Cadwalader allows sharing content.
Email to a friend or colleague:
From
To
Subject
Email Cadwalader represented Salix Pharmaceuticals, Ltd., a leading U.S. specialty pharmaceutical company, in its acquisition by Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) for $173.00 per share, or a total enterprise value of approximately $15.6 billion. The transaction was completed on April 1, 2015. https://www.cadwalader.com/news/news-release/cadwalader-represents-salix-pharmaceuticals-in-its-acquisition-by-valeant-pharmaceuticals